telmisartan has been researched along with Metabolic Syndrome in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 33 (50.00) | 29.6817 |
| 2010's | 32 (48.48) | 24.3611 |
| 2020's | 1 (1.52) | 2.80 |
| Authors | Studies |
|---|---|
| Avery, MA; Carvalho, PB; Chittiboyina, AG; Karamyan, VT; Kurtz, TW; Mizuno, CS; Patny, A; Pershadsingh, HA; Shah, FH; Speth, RC | 1 |
| Ammazzalorso, A; Amoia, P; Amoroso, R; Maccallini, C | 1 |
| Chen, W; Dang, C; Diao, D; Li, M; Wang, Y; Xie, X; Zhang, X | 1 |
| Budak, F; Guclu, M; Kiyici, S; Sigirli, D; Tuncel, E | 1 |
| Kagota, S; Kunitomo, M; Maruyama, K; Nakamura, K; Shinozuka, K; Tada, Y; Wakuda, H | 1 |
| Kinoshita, S; Nakamoto, H; Nishida, E; Ryuzaki, M; Sone, M | 1 |
| Barkhausen, J; Hübel, N; Mildner, M; Müller-Fielitz, H; Raasch, W; Vogt, FM | 1 |
| Hasegawa, Y; Katayama, T; Kim-Mitsuyama, S; Koibuchi, N; Ma, M; Nakagawa, T; Ogawa, H; Sueta, D; Toyama, K; Uekawa, K | 1 |
| Kagota, S; Maruyama, K; McGuire, JJ; Nakamura, K; Shinozuka, K; Wakuda, H; Yoshikawa, N | 1 |
| D'Amico, M; De Angelis, A; Di Filippo, C; Ferraraccio, F; Ferraro, B; Maisto, R; Rossi, C; Rotondo, A | 1 |
| Badar, VA; Bansode, VJ; Gore, PN; Hardas, MM | 1 |
| Abouzied, MM; Heeba, GH; Khalifa, MM; Rabie, EM | 1 |
| Dezortová, M; Hájek, M; Hill, M; Kratochvílová, S; Pelikánová, T; Škoch, A; Švehlíková, E; Wohl, P | 1 |
| Ali, EF; Mahdi, EA; Mahmoud, FA; Mostafa-Hedeab, G; Shahataa, MG | 1 |
| Cai, J; Cheng, S; Gao, L; Li, H; Li, M; Liu, P; Song, Y; Tian, G; Wang, Y; Yang, S; Yin, Y; Zhang, H | 1 |
| Dahlöf, B; Ritz, E | 1 |
| Kurtz, TW | 3 |
| Sharma, AM | 1 |
| Abe, H; Adachi, H; Hattori, S; Irino, H; Kitada, H; Miyatake, K; Morisawa, D; Noda, Y; Sasaki, T; Yasuoka, Y | 1 |
| Georgescu, EF | 1 |
| Kagota, S; Kunitomo, M; Nakamura, K; Nejime, N; Shinozuka, K; Tada, Y | 2 |
| Brillante, DG; Brillante, RE; Howes, LG; O'Sullivan, AJ | 1 |
| Bellomo, A; D'Ottavio, E; Formosa, V; Gianturco, V; Iori, A; Lo Iacono, C; Mancinella, M; Marigliano, V; Troisi, G | 1 |
| Bautz, W; Hornegger, J; Janka, R; Martirosian, P; Ritt, M; Schmieder, RE; Schneider, MP; Uder, M | 1 |
| Ebihara, K; Kusakabe, T; Kuwahara, K; Li, Y; Murray, M; Nakao, K; Naowaboot, J; Rong, X; Zhao, M | 1 |
| Aguila, MB; Cardoso-de-Lemos, FS; de Carvalho, L; Gregório, BM; Mandarim-de-Lacerda, CA; Souza-Mello, V | 1 |
| Hill, M; Klementová, M; Kopecký, J; Kratochvílová, S; Krusinová, E; Mlejnek, P; Neskudla, T; Pelikánová, T; Pravenec, M; Vrbíková, J; Wohl, P; Zídková, K | 1 |
| Frána, P; Plachý, M; Rihácek, I; Schwarz, D; Soucek, M | 1 |
| Awata, T; Ikebukuro, K; Inukai, K; Ito, D; Katayama, S; Kurihara, S; Ono, H; Sumita, T; Watanabe, M | 1 |
| Comi-Diaz, C; Macias-Batista, A; Martinez-Martin, FJ; Pedrianes-Martin, P; Rodriguez-Rosas, H; Soriano-Perera, P | 1 |
| Costo, A; Crespo, L; Doncel, C; Fernandez Toro, JM; Fraile, J; Rivas, MD; Sanchez Muñoz-Torrero, JF; Zamorano, J | 1 |
| Derosa, G; Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A | 1 |
| Imig, JD; Khan, AH | 1 |
| Brown, L; Sernia, C | 1 |
| Bähr, IN; Kappert, K; Kintscher, U; Krüger, J; Parhofer, KG; Schimkus, J; Scholze, J; Stark, RG; Tretter, P; Unger, T | 1 |
| Capuano, A; D'Amico, M; Di Filippo, C; Donniacuo, M; Ferraraccio, F; Rinaldi, B; Rossi, F; Sodano, L | 1 |
| Arimura, T; Fujisawa, K; Inoue, A; Kuwano, T; Matsunaga, E; Mitsutake, R; Miura, S; Morii, J; Nagata, I; Norimatsu, K; Saku, K; Shiga, Y; Shimizu, T; Shirotani, T; Uehara, Y | 1 |
| Horiguchi, CS; Makino, H; Miyoshi, T; Murakami, K; Nakamura, Y; Ogawa, D; Sasaki, M; Uchida, HA; Wada, J | 1 |
| Hirooka, Y; Kishi, T; Konno, S; Sunagawa, K | 1 |
| Ishikawa, M; Ishimitsu, T; Kobayashi, N; Onoda, S; Sugiyama, F | 1 |
| Corry, DB; Tuck, ML | 1 |
| Ivleva, AIa | 1 |
| Tuck, ML | 1 |
| Pershadsingh, HA | 1 |
| Battershill, AJ; Scott, LJ | 1 |
| Ando, H; Fujimura, A | 1 |
| Chazova, IE; Duishvili, DE; Mamyrbaeva, KM; Masenko, VP; Mychka, VB | 1 |
| Formoso, G; Hassan, H; Negro, R | 1 |
| Remuzzi, A; Remuzzi, G | 1 |
| Shimabukuro, M; Shimabukuro, T; Tanaka, H | 1 |
| Bahadir, MA; Bahadir, O; Oguz, A; Uzunlulu, M | 1 |
| Hoshide, S; Ishikawa, J; Ishikawa, S; Kanemaru, Y; Kario, K; Noguchi, C; Shimada, K; Tada, M; Takanori, H; Tukui, D; Yano, A; Yano, Y | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Fassi, R; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Ragonesi, PD; Salvadeo, SA | 1 |
| Ludvik, B; Tripp, B | 1 |
| Matsui, T; Nakamura, K; Yamagishi, S | 1 |
| Petkow-Dimitrow, P | 1 |
| Ichikawa, Y | 1 |
| Celoria, BM; Francischetti, A; Francischetti, EA; Genelhu, VA | 1 |
| Fujitani, Y; Hirose, T; Ikeda, F; Kawamori, R; Mita, T; Nakayama, S; Shimizu, T; Uchino, H; Watada, H | 1 |
| Grossman, E; Harari, A; Harats, D; Kamari, Y; Peleg, E; Shaish, A; Sharabi, Y | 1 |
| Inoue, T; Node, K | 1 |
14 review(s) available for telmisartan and Metabolic Syndrome
| Article | Year |
|---|---|
Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome.
Topics: Animals; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Humans; Hypertension; Hypoglycemic Agents; Metabolic Syndrome; Molecular Structure; PPAR gamma; Structure-Activity Relationship | 2019 |
Beyond the classic angiotensin-receptor-blocker profile.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Humans; Metabolic Syndrome; PPAR gamma; Receptor, Angiotensin, Type 1; Telmisartan | 2008 |
The value of current interventions for obesity.
Topics: Adipogenesis; Angiotensin II Type 1 Receptor Blockers; Bariatric Surgery; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Obesity; Risk Factors; Telmisartan; Weight Loss | 2008 |
Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Fatty Liver; Humans; Insulin Resistance; Losartan; Metabolic Syndrome; Renin-Angiotensin System; Telmisartan; Tetrazoles | 2008 |
Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypertension; Metabolic Syndrome; PPAR gamma; Telmisartan | 2005 |
[New perspectives of preventive pharmacotherapy in metabolic syndrome].
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Humans; Hypertension; Insulin; Lipoproteins; Metabolic Syndrome; Telmisartan | 2005 |
Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; PPAR gamma; Telmisartan | 2005 |
Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Irbesartan; Losartan; Metabolic Syndrome; PPAR gamma; Telmisartan; Tetrazoles | 2006 |
Telmisartan: a review of its use in the management of hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Humans; Hydrochlorothiazide; Hypertension; Hypertension, Renal; Metabolic Syndrome; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Telmisartan | 2006 |
New treatment strategies for patients with hypertension and insulin resistance.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atherosclerosis; Benzimidazoles; Benzoates; Coronary Artery Disease; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; Metabolic Syndrome; PPAR gamma; Renin-Angiotensin System; Telmisartan | 2006 |
Potential protective effects of telmisartan on renal function deterioration.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Humans; Kidney Diseases; Metabolic Syndrome; Telmisartan | 2006 |
Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Glycation End Products, Advanced; Humans; Metabolic Syndrome; PPAR gamma; Renin-Angiotensin System; Telmisartan | 2007 |
[New therapeutic targets for ACE inhibitors and angiotensin receptor blockers].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertension; Losartan; Metabolic Syndrome; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Risk Reduction Behavior; Telmisartan; Treatment Outcome | 2007 |
Treatment of hypertension in individuals with the cardiometabolic syndrome: role of an angiotensin II receptor blocker, telmisartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Diet, Reducing; Female; Humans; Hypertension; Life Style; Male; Meta-Analysis as Topic; Metabolic Syndrome; Prevalence; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Survival Analysis; Telmisartan; Treatment Outcome | 2008 |
23 trial(s) available for telmisartan and Metabolic Syndrome
| Article | Year |
|---|---|
Even Short-Term Telmisartan Treatment Ameliorated Insulin Resistance But Had No Influence on Serum Adiponectin and Tumor Necrosis Factor-Alpha Levels in Hypertensive Patients with Metabolic Syndrome.
Topics: Adiponectin; Adolescent; Adult; Aged; Antihypertensive Agents; Drug Administration Schedule; Female; Humans; Hypertension; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Telmisartan; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2019 |
Effectiveness of using long-acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hypertension monitoring by using telemedicine system (FUJIYAMA study).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cholesterol, LDL; Female; Humans; Hypertension; Japan; Male; Metabolic Syndrome; Middle Aged; Obesity; Prospective Studies; Telemedicine; Telmisartan; Tetrazoles | 2014 |
Comparative effect of telmisartan vs lisinopril on blood pressure in patients of metabolic syndrome.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Female; Humans; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Telmisartan | 2015 |
Intramyocellular lipid content in subjects with impaired fasting glucose after telmisartan treatment, a randomised cross-over trial.
Topics: Adipokines; Adiponectin; Adult; Benzimidazoles; Benzoates; Blood Glucose; Calorimetry; Cholesterol; Cross-Over Studies; Cytoplasm; Double-Blind Method; Glucose Clamp Technique; Humans; Insulin; Insulin Resistance; Lipids; Magnetic Resonance Spectroscopy; Male; Metabolic Syndrome; Middle Aged; Muscles; Telmisartan | 2016 |
Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Chronic Disease; Female; Glycated Hemoglobin; Heart Failure; Heart Rate; Humans; Hypertension; Imidazoles; Lipid Metabolism; Lipids; Longitudinal Studies; Male; Metabolic Syndrome; Middle Aged; Natriuretic Peptide, Brain; Telmisartan; Tetrazoles | 2008 |
Effects of cardiovascular angiotensin II type 1 receptor blockade on nitric oxide synthase inhibition in patients with insulin resistance syndrome.
Topics: Adult; Angiotensin II; Arteries; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular System; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hemodynamics; Humans; Insulin Resistance; Male; Metabolic Syndrome; Nitric Oxide Synthase; omega-N-Methylarginine; Photoplethysmography; Receptor, Angiotensin, Type 1; Telmisartan; Vascular Resistance | 2009 |
The treatment of hypertension with telmisartan in the sphere of circadian rhythm in metabolic syndrome in the elderly.
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Circadian Rhythm; Follow-Up Studies; Humans; Hypertension; Metabolic Syndrome; Prospective Studies; Telmisartan; Treatment Outcome | 2009 |
Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose.
Topics: Adipokines; Adult; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Glucose; Glucose Clamp Technique; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Telmisartan | 2010 |
[The normalized smoothness index and parametric population RDH index of telmisartane in patients with newly diagnosed hypertension and metabolic syndrome].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; Humans; Hypertension; Male; Metabolic Syndrome; Middle Aged; Telmisartan | 2010 |
Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Homeostasis; Humans; Hypertension; Insulin Resistance; Japan; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Obesity; Oxidative Stress; PPAR gamma; Telmisartan; Tetrazoles | 2010 |
Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Blood Pressure; Dihydropyridines; Drug Combinations; Female; Humans; Hypertension; Insulin Resistance; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Nitrobenzenes; Piperazines; Prospective Studies; Spain; Telmisartan | 2011 |
Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; Benzoates; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Metabolic Syndrome; Prospective Studies; Ramipril; Secondary Prevention; Severity of Illness Index; Telmisartan; Treatment Outcome | 2012 |
High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome.
Topics: Adult; Angiotensin II Type 2 Receptor Blockers; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Benzimidazoles; Benzoates; Blood Pressure; CD36 Antigens; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Interleukin-6; Male; Metabolic Syndrome; Middle Aged; Monocytes; Pioglitazone; PPAR gamma; Receptors, Cell Surface; Telmisartan; Thiazolidinediones | 2011 |
Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Dosage Forms; Dose-Response Relationship, Drug; Drug Combinations; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Male; Metabolic Syndrome; Potassium; Telmisartan; Treatment Outcome; Uric Acid | 2012 |
The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension: Abdominal fat Depot Intervention Program of Okayama (ADIPO).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Female; Humans; Hypertension; Insulin Resistance; Intra-Abdominal Fat; Male; Metabolic Syndrome; Middle Aged; PPAR gamma; Subcutaneous Fat; Telmisartan; Tetrazoles; Tomography, X-Ray Computed; Treatment Outcome; Valine; Valsartan; Waist Circumference | 2013 |
Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Flow Velocity; Blood Pressure; Diet Therapy; Endothelium, Vascular; Female; Forearm; Humans; Hypertension; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Sympathetic Nervous System; Telmisartan; Tetrazoles; Vascular Resistance; Vasodilation | 2012 |
The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients.
Topics: Adiponectin; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; Cholesterol; Fatty Acids, Nonesterified; Female; Humans; Insulin; Irbesartan; Male; Metabolic Syndrome; Middle Aged; Telmisartan; Tetrazoles; Triglycerides | 2006 |
Effects of telmisartan on fat distribution in individuals with the metabolic syndrome.
Topics: Adipose Tissue, White; Adult; Aged; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Aorta; Benzimidazoles; Benzoates; Biomarkers; Blood Glucose; Blood Pressure; Body Fat Distribution; Calcium Channel Blockers; Female; Glucose Tolerance Test; Humans; Hypertension; Insulin; Insulin Resistance; Intra-Abdominal Fat; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Research Design; Telmisartan; Tomography, X-Ray Computed; Treatment Outcome; Vascular Resistance | 2007 |
Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Cholesterol, HDL; Fasting; Female; Humans; Hypertension; Insulin Resistance; Losartan; Male; Metabolic Syndrome; Middle Aged; Telmisartan | 2007 |
The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; C-Reactive Protein; Female; Humans; Hypertension; Inflammation; Male; Metabolic Syndrome; PPAR gamma; Telmisartan; Treatment Outcome | 2007 |
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
Topics: Adiponectin; Administration, Oral; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Irbesartan; Lipids; Male; Metabolic Syndrome; Resistin; Rosiglitazone; Telmisartan; Tetrazoles; Thiazolidinediones; Treatment Outcome | 2007 |
[Antihypertensive and metabolic effects of telmisartan in patients with the metabolic syndrome in primary care--a field study].
Topics: Aged; Antihypertensive Agents; Austria; Benzimidazoles; Benzoates; Comorbidity; Female; Humans; Hypertension; Male; Metabolic Syndrome; Middle Aged; Prevalence; Primary Health Care; Risk Assessment; Risk Factors; Telmisartan; Treatment Outcome | 2007 |
Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Female; Humans; Hypertension; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
29 other study(ies) available for telmisartan and Metabolic Syndrome
| Article | Year |
|---|---|
Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Cell Membrane; Cells, Cultured; Drug Design; Liver; Metabolic Syndrome; Models, Chemical; PPAR gamma; Radioligand Assay; Rats; Receptor, Angiotensin, Type 1; Transcriptional Activation | 2010 |
Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; B7-H1 Antigen; Biomarkers, Tumor; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Metabolic Syndrome; Obesity; Rats; Rats, Wistar; Telmisartan; Triple Negative Breast Neoplasms | 2020 |
Abnormal amounts of intracellular calcium regulatory proteins in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome and cardiac dysfunction.
Topics: Animals; Benzimidazoles; Benzoates; Blood Glucose; Body Weight; Calcium; Calcium-Binding Proteins; Cholesterol; Coronary Circulation; Diastole; Disease Models, Animal; Heart Function Tests; Insulin; Male; Metabolic Syndrome; Myocytes, Cardiac; Phosphorylation; Rats; Rats, Inbred Strains; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Serine; Telmisartan; Triglycerides; Ventricular Dysfunction; Ventricular Function, Left | 2013 |
Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Obesity Agents; Antihypertensive Agents; Behavior, Animal; Benzimidazoles; Benzoates; Diet, High-Fat; Dietary Sucrose; Drug Therapy, Combination; Energy Intake; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Obesity; Random Allocation; Rats; Rats, Inbred SHR; Telmisartan; Weight Gain | 2014 |
Telmisartan exerts sustained blood pressure control and reduces blood pressure variability in metabolic syndrome by inhibiting sympathetic activity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Nervous System; Baroreflex; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Determination; Circadian Rhythm; Disease Models, Animal; Equipment Design; Hypertension; Metabolic Syndrome; Rats; Rats, Inbred SHR; Telemetry; Telmisartan | 2014 |
Disturbance of vasodilation via protease-activated receptor 2 in SHRSP.Z-Lepr fa/IzmDmcr rats with metabolic syndrome.
Topics: Animals; Benzimidazoles; Benzoates; Blood Pressure; Disease Models, Animal; Guanylate Cyclase; Male; Mesenteric Arteries; Metabolic Syndrome; Nitric Oxide; Nitroprusside; Oligopeptides; Oxidative Stress; Rats; Rats, Inbred WKY; Receptor, PAR-2; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Telmisartan; Thiobarbituric Acid Reactive Substances; Vasodilation | 2014 |
Involvement of proteasome and macrophages M2 in the protection afforded by telmisartan against the acute myocardial infarction in Zucker diabetic fatty rats with metabolic syndrome.
Topics: Animals; Benzimidazoles; Benzoates; Macrophages; Metabolic Syndrome; Myocardial Infarction; Proteasome Endopeptidase Complex; Rats; Rats, Zucker; Telmisartan | 2014 |
Comparative effects of Aliskiren and Telmisartan in high fructose diet-induced metabolic syndrome in rats.
Topics: Amides; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Glucose; Fructose; Fumarates; Insulin Resistance; Male; Metabolic Syndrome; Rats; Rats, Wistar; Telmisartan; Treatment Outcome | 2015 |
Effects of telmisartan and pioglitazone on high fructose induced metabolic syndrome in rats.
Topics: Animals; Benzimidazoles; Benzoates; Blood Glucose; Drug Therapy, Combination; Fructose; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Pioglitazone; Rats; Rats, Sprague-Dawley; Telmisartan; Thiazolidinediones; Treatment Outcome | 2016 |
Telmisartan Ameliorates Nephropathy in Metabolic Syndrome by Reducing Leptin Release From Perirenal Adipose Tissue.
Topics: Adipogenesis; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal; Intra-Abdominal Fat; Kidney Diseases; Leptin; Male; Metabolic Syndrome; Protective Agents; Rats; Rats, Wistar; Telmisartan | 2016 |
A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Body Size; Cardiovascular Diseases; Humans; Life Style; Metabolic Syndrome; Obesity; Ramipril; Renin-Angiotensin System; Risk Assessment; Risk Factors; Telmisartan | 2008 |
Chronic production of peroxynitrite in the vascular wall impairs vasorelaxation function in SHR/NDmcr-cp rats, an animal model of metabolic syndrome.
Topics: Acetylcholine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Blood Vessels; Blotting, Western; Enzyme Activation; Immunoenzyme Techniques; Luminescence; Male; Metabolic Syndrome; NADPH Oxidases; Nitric Oxide Synthase Type III; Nitroprusside; Peroxynitrous Acid; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Telmisartan; Tyrosine; Vasoconstrictor Agents; Vasodilation | 2009 |
Measurement of kidney perfusion by magnetic resonance imaging: comparison of MRI with arterial spin labeling to para-aminohippuric acid plasma clearance in male subjects with metabolic syndrome.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Benzoates; Blood Pressure; Creatinine; Hemodynamics; Humans; Kidney; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Middle Aged; p-Aminohippuric Acid; Renal Circulation; Renal Plasma Flow; Spin Labels; Telmisartan; Young Adult | 2010 |
Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice.
Topics: Adipocytes; Adipose Tissue, White; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Cell Size; Diet, High-Fat; Fatty Liver; Insulin; Insulin Resistance; Leptin; Lipids; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Skeletal; Obesity, Abdominal; Organ Size; PPAR gamma; Receptor, Angiotensin, Type 1; Telmisartan; Triglycerides | 2010 |
Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Drug Therapy, Combination; Energy Intake; Glucose Tolerance Test; Hypoglycemic Agents; Insulin Resistance; Liver; Male; Metabolic Syndrome; Metformin; Mice; Mice, Inbred C57BL; Obesity; Pancreas; Pyrazines; Sitagliptin Phosphate; Telmisartan; Triazoles | 2010 |
Telmisartan improves insulin resistance in patients with low cytokine levels.
Topics: Adult; Benzimidazoles; Benzoates; Biomarkers; Blood Glucose; Cytokines; Female; Humans; Hypertension; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Telmisartan | 2011 |
Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Body Weight; Dietary Fats; Disease Models, Animal; Hypertension; Kidney Diseases; Male; Metabolic Syndrome; PPAR gamma; Rats; Rats, Inbred SHR; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood; Blood Glucose; Blood Pressure; Cholesterol; Crosses, Genetic; Guanylate Cyclase; Hypoglycemic Agents; Insulin; Male; Mesenteric Arteries; Metabolic Syndrome; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Nitroprusside; Phenylephrine; Pioglitazone; Rats; Rats, Inbred SHR; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Telmisartan; Thiazolidinediones; Triglycerides; Tyrosine; Vasoconstriction; Vasodilation | 2011 |
Emerging benefits of AT1 receptor antagonists with pleiotropic anti-inflammatory activity.
Topics: Animals; Benzimidazoles; Benzoates; Hypertension; Kidney Diseases; Male; Metabolic Syndrome; Telmisartan; Tetrazoles; Valine; Valsartan | 2011 |
Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in Zucker diabetic fatty rats with metabolic syndrome.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Cardiotonic Agents; Disease Models, Animal; Heart; Immunohistochemistry; Metabolic Syndrome; Myocardial Reperfusion Injury; NF-kappa B; PPAR gamma; Rats; Rats, Zucker; Telmisartan; Troponin I; Tumor Necrosis Factor-alpha | 2012 |
Renoprotective mechanisms of telmisartan on renal injury and inflammation in SHRSP.Z-Leprfa/IzmDmcr rats.
Topics: Animals; Benzimidazoles; Benzoates; Cell Cycle Proteins; Desmin; Epithelial-Mesenchymal Transition; Hydralazine; Kidney Diseases; Male; Metabolic Syndrome; Nephritis; Podocytes; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Smad4 Protein; Telmisartan; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2013 |
The metabolic effects of angiotensin-receptor blockers.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cells, Cultured; Disease Models, Animal; DNA, Complementary; Gene Expression; Male; Metabolic Syndrome; Mice; Polymerase Chain Reaction; PPAR gamma; Rats; Rats, Sprague-Dawley; Telmisartan | 2005 |
[Telmisartan].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 2; Humans; Hypertension; Lipids; Metabolic Syndrome; PPAR gamma; Randomized Controlled Trials as Topic; Telmisartan | 2005 |
[In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertension; Metabolic Syndrome; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan; Time Factors | 2006 |
[PPARgamma-activating properties of angiotensin receptor blockers].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arteriosclerosis; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Insulin Resistance; Irbesartan; Metabolic Syndrome; PPAR gamma; Randomized Controlled Trials as Topic; Telmisartan; Tetrazoles | 2006 |
[The role of telmisartan in the treatment of metabolic syndrome].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biomarkers; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Mass Index; Cholesterol; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Male; Metabolic Syndrome; PPAR gamma; Telmisartan; Treatment Outcome | 2006 |
Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazoles; Inflammation; Japan; Male; Metabolic Syndrome; Middle Aged; Telmisartan; Tetrazoles | 2008 |
Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Diet; Fructose; Hyperinsulinism; Hyperlipidemias; Hypertension; Insulin; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Telmisartan; Triglycerides | 2008 |
Telmisartan as a metabolic sartan for targeting vascular failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Cholesterol; Glucose; Humans; Hypertriglyceridemia; Metabolic Syndrome; PPAR gamma; Risk Factors; Telmisartan | 2008 |